Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1832448rdf:typepubmed:Citationlld:pubmed
pubmed-article:1832448lifeskim:mentionsumls-concept:C1123023lld:lifeskim
pubmed-article:1832448lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1832448lifeskim:mentionsumls-concept:C0027740lld:lifeskim
pubmed-article:1832448lifeskim:mentionsumls-concept:C0036421lld:lifeskim
pubmed-article:1832448lifeskim:mentionsumls-concept:C0034735lld:lifeskim
pubmed-article:1832448lifeskim:mentionsumls-concept:C0200765lld:lifeskim
pubmed-article:1832448pubmed:issue3lld:pubmed
pubmed-article:1832448pubmed:dateCreated1991-10-11lld:pubmed
pubmed-article:1832448pubmed:abstractTextImage analysis quantification was used to assess the results of immunocytochemistry for a neuronal marker and neuropeptides in digital skin biopsies from Raynaud's phenomenon (RP) and systemic sclerosis (SS) patients, to verify the possibility of a selective quantitative abnormality of immunoreactive nerves. The field area of specific immunostaining and nerve counts were evaluated on coded specimens, and the data compared by statistical analysis. Nerves immunoreactive for protein gene product 9.5 (PGP), a marker for neuronal elements, were decreased significantly in epidermal and subepidermal layers of digital skin in RP patients (P less than 0.0001). This change was paralleled by a decrease of calcitonin gene-related peptide (CGRP) immunoreactive nerves in the epidermis and around capillaries in the dermal papillae (P = 0.005). In the skin of RP patients, these changes were readily demonstrated by image analysis, although they were not always apparent on visual screening. In digital skin of SS patients, there was a generalized and very significant decrease of PGP, CGRP, and VIP immunoreactivities in all areas (P less than 0.0001). These results demonstrate that neuropeptide-containing nerves are involved in the digital pathology of RP and SS, and that image analysis quantification is an accurate and sensitive method for assessing morphological changes in pathological samples.lld:pubmed
pubmed-article:1832448pubmed:languageenglld:pubmed
pubmed-article:1832448pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1832448pubmed:citationSubsetIMlld:pubmed
pubmed-article:1832448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1832448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1832448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1832448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1832448pubmed:statusMEDLINElld:pubmed
pubmed-article:1832448pubmed:monthJullld:pubmed
pubmed-article:1832448pubmed:issn0022-3417lld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:PolakJ MJMlld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:DowdP MPMlld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:SpringallD...lld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:LiuY FYFlld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:CowenTTlld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:TerenghiGGlld:pubmed
pubmed-article:1832448pubmed:authorpubmed-author:BunkerC BCBlld:pubmed
pubmed-article:1832448pubmed:issnTypePrintlld:pubmed
pubmed-article:1832448pubmed:volume164lld:pubmed
pubmed-article:1832448pubmed:ownerNLMlld:pubmed
pubmed-article:1832448pubmed:authorsCompleteYlld:pubmed
pubmed-article:1832448pubmed:pagination245-52lld:pubmed
pubmed-article:1832448pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:meshHeadingpubmed-meshheading:1832448-...lld:pubmed
pubmed-article:1832448pubmed:year1991lld:pubmed
pubmed-article:1832448pubmed:articleTitleImage analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis.lld:pubmed
pubmed-article:1832448pubmed:affiliationHistochemistry Department, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.lld:pubmed
pubmed-article:1832448pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1832448pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1832448lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1832448lld:pubmed